Eli Lilly to acquire developer of hearing loss gene therapy for up to USD 610m
The US-based drugmaker has entered an agreement to purchase Akouos, which is developing gene therapies to restore hearing loss.
by marketwire, translated by daniel pedersen
Eli Lilly announced on Tuesday that it had entered a definite agreement with Akouos to purchase the company for a price that could reach USD 610m.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sensorion initiates study of hearing loss therapy candidate
For subscribers
